Clinical Trial Update: Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a phase 1/2 study evaluating universal CD19-targeting CAR-γδT cells for refractory autoimmune diseases, currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Antiphospholipid Syndrome
• Inflammatory Myopathies
• Sjogren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• CAR-γδT cells targeting CD19 (CAR-γδT cell therapy encoding anti-CD19 specificity)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1, Phase 2 | Status: RECRUITING